[Expression and role of peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in pulmonary fibrosis].
OBJECTIVE
To evaluate the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and nuclear factor-kappaB (NF-kappaB) in lungs in patients with pulmonary fibrosis, and to explore their effect on the pathogenesis of pulmonary fibrosis.


METHODS
Immunohistochemical technology was performed to investigate the PPARgamma and NF-kappaB expression in lung specimens from 16 cases of pulmonary fibrosis and 10 cases of normal controls.


RESULTS
The positive score of PPARgamma (0.35+/- 0.08) in fibrosis group was lower than that in control group (0.42+/-0.04, P<0.05). The positive score of NF-kappaB (0.51+/- 0.11) in fibrosis group was higher than that in control group (0.38+/-0.04, P<0.05). There was negative correlation between PPARgamma and NF-kappaB expression in fibrosis group (P<0.05).


CONCLUSIONS
The decreased expression of PPARgamma and enhanced expression of NF-kappaB play a role in the pathogenesis of pulmonary fibrosis, which may provide a new idea for treating this disease.
Lin
Qing
Q
Department Geriatrics, Peking University First Hospital, Beijing 100034, China.
Ni
Lian Fang
LF
Ren
Ya Li
YL
Liu
Xin Min
XM
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000378:metabolism*; D047495:PPAR gamma / Q000378:metabolism*; D011658:Pulmonary Fibrosis / Q000378:metabolism*
D016328:NF-kappa B; D047495:PPAR gamma